Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells

Lorenz C. Hofbauer, Chaoxiang Shui, B. Lawrence Riggs, Colin R. Dunstan, Thomas C. Spelsberg, Timothy O'Brien, Sundeep Khosla

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

Osteoporosis and vasculopathy are common after organ transplantation and have been largely attributed to the use of immununosuppressants. Osteoprotegerin (OPG) is produced by osteoblastic and arterial cells, and inhibits osteoclast functions by neutralizing receptor activator of NF-κB ligand (RANKL). Because OPG-deficient mice develop osteoporosis and arterial calcification, we assessed the effects of immunosuppressants on OPG and RANKL expression by human osteoblastic and coronary artery smooth muscle cells (CASMC). Cyclosporine A, rapamycin, and FK-506 decreased OPG mRNA and protein levels in undifferentiated marrow stromal cells (by 63, 44, and 68%, respectively, P < 0.001). All three immunosuppressants increased RANKL mRNA levels in these cells by 60 to 210%. In contrast to these effects on marrow stromal cells, rapamycin, which may be relatively bone-sparing, increased OPG mRNA and protein production (by 120%, P < 0.001) in mature osteoblastic cells. Cyclosporine A also decreased OPG mRNA and protein production (by 52%, P < 0.001) of CASMC. In conclusion, immunosuppressants decrease OPG mRNA and protein production and increase RANKL gene expression by marrow stromal cells, and cyclosporine suppresses OPG production in CASMC. These studies thus provide a potential mechanism for immunosuppressant-induced bone loss, and the propensity of cyclosporine A to cause vascular disease.

Original languageEnglish (US)
Pages (from-to)334-339
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume280
Issue number1
DOIs
StatePublished - 2001

Fingerprint

RANK Ligand
Osteoprotegerin
Immunosuppressive Agents
Smooth Muscle Myocytes
Muscle
Coronary Vessels
Cells
Cyclosporine
Stromal Cells
Messenger RNA
Bone Marrow
Sirolimus
Osteoporosis
Bone
Proteins
Transplantation (surgical)
Bone and Bones
human TNFSF11 protein
Tacrolimus
Organ Transplantation

Keywords

  • Cyclosporine A
  • Osteoblasts
  • Osteoprotegerin
  • Rapamycin
  • Smooth muscle cell
  • Stromal cell

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. / Hofbauer, Lorenz C.; Shui, Chaoxiang; Riggs, B. Lawrence; Dunstan, Colin R.; Spelsberg, Thomas C.; O'Brien, Timothy; Khosla, Sundeep.

In: Biochemical and Biophysical Research Communications, Vol. 280, No. 1, 2001, p. 334-339.

Research output: Contribution to journalArticle

Hofbauer, Lorenz C. ; Shui, Chaoxiang ; Riggs, B. Lawrence ; Dunstan, Colin R. ; Spelsberg, Thomas C. ; O'Brien, Timothy ; Khosla, Sundeep. / Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. In: Biochemical and Biophysical Research Communications. 2001 ; Vol. 280, No. 1. pp. 334-339.
@article{d673471259884cc48e6c343b80867c39,
title = "Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells",
abstract = "Osteoporosis and vasculopathy are common after organ transplantation and have been largely attributed to the use of immununosuppressants. Osteoprotegerin (OPG) is produced by osteoblastic and arterial cells, and inhibits osteoclast functions by neutralizing receptor activator of NF-κB ligand (RANKL). Because OPG-deficient mice develop osteoporosis and arterial calcification, we assessed the effects of immunosuppressants on OPG and RANKL expression by human osteoblastic and coronary artery smooth muscle cells (CASMC). Cyclosporine A, rapamycin, and FK-506 decreased OPG mRNA and protein levels in undifferentiated marrow stromal cells (by 63, 44, and 68{\%}, respectively, P < 0.001). All three immunosuppressants increased RANKL mRNA levels in these cells by 60 to 210{\%}. In contrast to these effects on marrow stromal cells, rapamycin, which may be relatively bone-sparing, increased OPG mRNA and protein production (by 120{\%}, P < 0.001) in mature osteoblastic cells. Cyclosporine A also decreased OPG mRNA and protein production (by 52{\%}, P < 0.001) of CASMC. In conclusion, immunosuppressants decrease OPG mRNA and protein production and increase RANKL gene expression by marrow stromal cells, and cyclosporine suppresses OPG production in CASMC. These studies thus provide a potential mechanism for immunosuppressant-induced bone loss, and the propensity of cyclosporine A to cause vascular disease.",
keywords = "Cyclosporine A, Osteoblasts, Osteoprotegerin, Rapamycin, Smooth muscle cell, Stromal cell",
author = "Hofbauer, {Lorenz C.} and Chaoxiang Shui and Riggs, {B. Lawrence} and Dunstan, {Colin R.} and Spelsberg, {Thomas C.} and Timothy O'Brien and Sundeep Khosla",
year = "2001",
doi = "10.1006/bbrc.2000.4130",
language = "English (US)",
volume = "280",
pages = "334--339",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells

AU - Hofbauer, Lorenz C.

AU - Shui, Chaoxiang

AU - Riggs, B. Lawrence

AU - Dunstan, Colin R.

AU - Spelsberg, Thomas C.

AU - O'Brien, Timothy

AU - Khosla, Sundeep

PY - 2001

Y1 - 2001

N2 - Osteoporosis and vasculopathy are common after organ transplantation and have been largely attributed to the use of immununosuppressants. Osteoprotegerin (OPG) is produced by osteoblastic and arterial cells, and inhibits osteoclast functions by neutralizing receptor activator of NF-κB ligand (RANKL). Because OPG-deficient mice develop osteoporosis and arterial calcification, we assessed the effects of immunosuppressants on OPG and RANKL expression by human osteoblastic and coronary artery smooth muscle cells (CASMC). Cyclosporine A, rapamycin, and FK-506 decreased OPG mRNA and protein levels in undifferentiated marrow stromal cells (by 63, 44, and 68%, respectively, P < 0.001). All three immunosuppressants increased RANKL mRNA levels in these cells by 60 to 210%. In contrast to these effects on marrow stromal cells, rapamycin, which may be relatively bone-sparing, increased OPG mRNA and protein production (by 120%, P < 0.001) in mature osteoblastic cells. Cyclosporine A also decreased OPG mRNA and protein production (by 52%, P < 0.001) of CASMC. In conclusion, immunosuppressants decrease OPG mRNA and protein production and increase RANKL gene expression by marrow stromal cells, and cyclosporine suppresses OPG production in CASMC. These studies thus provide a potential mechanism for immunosuppressant-induced bone loss, and the propensity of cyclosporine A to cause vascular disease.

AB - Osteoporosis and vasculopathy are common after organ transplantation and have been largely attributed to the use of immununosuppressants. Osteoprotegerin (OPG) is produced by osteoblastic and arterial cells, and inhibits osteoclast functions by neutralizing receptor activator of NF-κB ligand (RANKL). Because OPG-deficient mice develop osteoporosis and arterial calcification, we assessed the effects of immunosuppressants on OPG and RANKL expression by human osteoblastic and coronary artery smooth muscle cells (CASMC). Cyclosporine A, rapamycin, and FK-506 decreased OPG mRNA and protein levels in undifferentiated marrow stromal cells (by 63, 44, and 68%, respectively, P < 0.001). All three immunosuppressants increased RANKL mRNA levels in these cells by 60 to 210%. In contrast to these effects on marrow stromal cells, rapamycin, which may be relatively bone-sparing, increased OPG mRNA and protein production (by 120%, P < 0.001) in mature osteoblastic cells. Cyclosporine A also decreased OPG mRNA and protein production (by 52%, P < 0.001) of CASMC. In conclusion, immunosuppressants decrease OPG mRNA and protein production and increase RANKL gene expression by marrow stromal cells, and cyclosporine suppresses OPG production in CASMC. These studies thus provide a potential mechanism for immunosuppressant-induced bone loss, and the propensity of cyclosporine A to cause vascular disease.

KW - Cyclosporine A

KW - Osteoblasts

KW - Osteoprotegerin

KW - Rapamycin

KW - Smooth muscle cell

KW - Stromal cell

UR - http://www.scopus.com/inward/record.url?scp=0034817070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034817070&partnerID=8YFLogxK

U2 - 10.1006/bbrc.2000.4130

DO - 10.1006/bbrc.2000.4130

M3 - Article

C2 - 11162519

AN - SCOPUS:0034817070

VL - 280

SP - 334

EP - 339

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -